TP53 and breast cancer: Secondly, the OncoCarta panel interrogates a finite number of mutations; for example, although TP53 is the second most frequently mutated gene after the PI3KCA proto-oncogene occurring in approximately 23% of breast cancer samples [27], it was not included in our assay panel.